NYSE American - Delayed Quote USD

NanoViricides, Inc. (NNVC)

Get top stock picks

1.1200 -0.0300 (-2.61%)

At close: September 4 at 4:00:00 PM EDT

1.1099 -0.0101 (-0.90%)

After hours: September 4 at 7:49:17 PM EDT

Get top stock picks

While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles

ACCESS Newswire 7d ago

NNVC
-2.61%
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

ACCESS Newswire 28d ago

NNVC
-2.61%
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo

ACCESS Newswire 1mo ago

NNVC
-2.61%
NanoViricides: Fiscal Q2 Earnings Snapshot

Associated Press Finance 6mo ago

NNVC
-2.61%
NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering

ACCESS Newswire 3mo ago

NNVC
-2.61%
REPLAY: Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan

IPO-Edge.com 2mo ago

NNVC
-2.61%
PFE

MRK
NanoViricides closes $2M direct offering

Proactive 3mo ago

NNVC
-2.61%
Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs

Exec Edge 3mo ago

NNVC
-2.61%
PPSI

COYA
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies

ACCESS Newswire 2mo ago

NNVC
-2.61%
NanoViricides seeks FDA orphan status for MPox drug

Proactive 6mo ago

NNVC
-2.61%
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering

ACCESS Newswire 3mo ago

NNVC
-2.61%
NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference

TMX Newsfile 4mo ago

NNVC
-2.61%

Yahoo Finance

U.S. markets closed

NanoViricides, Inc. (NNVC)

While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo

NanoViricides: Fiscal Q2 Earnings Snapshot

NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering

REPLAY: Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan

NanoViricides closes $2M direct offering

Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies

NanoViricides seeks FDA orphan status for MPox drug

NanoViricides Announces Closing of ~$2 Million Registered Direct Offering

NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference